According to the Market Statsville Group (MSG), the global hydroxyethyl starch solutions market size is expected to grow at a CAGR of 5.6% from 2023 to 2033.
The HES solutions market is the increasing prevalence of hypovolemia and related conditions. These conditions can be caused by various factors, including surgery, trauma, and sepsis. As a result, the demand for HES solutions is expected to increase as more people are diagnosed with these conditions and require treatment. Another driver of the HES solutions market is the growing number of surgeries and medical procedures performed worldwide. Many surgical procedures require the administration of fluids to maintain proper blood volume and prevent hypovolemia. HES solutions are often used in these situations, and as the number of surgeries and medical procedures increases, so does the demand for HES solutions. The rising demand for minimally invasive surgeries and procedures creates a lucrative growth opportunity for the market. These types of procedures require smaller amounts of fluids, and HES solutions can be particularly useful in these situations due to their ability to expand blood volume quickly.
Hydroxyethyl starch (HES) solutions are a type of intravenous fluid used in medical settings to treat hypovolemia or low blood volume. These solutions are made from modified starches and are typically administered through a vein. HES solutions work by expanding the blood plasma volume, which helps increase blood pressure and maintain organ perfusion. HES solutions are often used in surgical settings or to treat conditions such as sepsis or trauma. However, using HES solutions has been associated with some safety concerns, including an increased risk of kidney damage and mortality in certain patient populations. As a result, their use is generally recommended only when other treatments are unavailable or ineffective and under the supervision of a healthcare professional.
The pandemic has increased the demand for intravenous fluids, including HES solutions, due to the many patients requiring hospitalization for COVID-19. On the other hand, the safety concerns associated with using HES solutions have led to a decline in their use in some regions. In the early stages of the pandemic, the demand for HES solutions increased as hospitals and healthcare facilities experienced a surge in patients with COVID-19. Many of these patients required intravenous fluids to maintain blood pressure and prevent dehydration, and HES solutions were sometimes used. However, as more research was conducted on the safety of HES solutions, some healthcare providers and regulatory bodies began to restrict their use.
In May 2020, the European Medicines Agency (EMA) recommended that HES solutions be suspended in critically ill patients due to an increased risk of kidney injury and mortality. This recommendation was based on the results of several clinical trials that had raised concerns about the safety of HES solutions, particularly in patients with sepsis or kidney disease. Following the EMA's recommendation, several other countries also restricted using HES solutions. The impact of these restrictions on the global HES solutions market has been mixed. While the restrictions have led to a decline in the use of HES solutions in some regions, the overall impact on the market has been somewhat mitigated by the continued demand for intravenous fluids during the pandemic. In addition, ongoing research is being conducted to evaluate the safety and efficacy of HES solutions, and some experts believe that HES solutions may may create a growth in the treatment of various severe condition.
The increasing prevalence of hypovolemia and related conditions is a major driver for the hydroxyethyl starch (HES) solutions market growth. Hypovolemia is a condition characterized by a decreased blood volume, which can lead to a decrease in blood pressure and organ perfusion. This condition can be caused by various of factors, such as trauma, bleeding, sepsis, and surgical procedures, among others. According to data from the World Health Organization (WHO), severe sepsis affects more than 30 million people worldwide each year and is a leading cause of mortality in intensive care units. Additionally, surgical procedures, which often require the administration of intravenous fluids such as HES solutions, are performed on over 300 million people globally each year.
Moreover, certain patient populations are at an increased risk of developing hypovolemia and related conditions, such as older adults and patients with chronic kidney disease. These patients may require intravenous fluids to maintain blood volume and prevent hypovolemia. Therefore, the demand for HES solutions is expected to continue to rise in the forthcoming years. Thus, the increasing prevalence of hypovolemia and related conditions, coupled with the growing number of surgical procedures and vulnerable patient populations, are driving the growth of the HES solutions market. As the demand for these solutions continues to rise, innovations and developments in the field will likely emerge to meet the evolving needs of patients and healthcare providers.
One of the major restraining factors for the hydroxyethyl starch (HES) solutions market is the increasing concern regarding the safety and efficacy of HES solutions. HES solutions have been linked to several adverse events, such as kidney injury, bleeding, and increased mortality, particularly in patients with sepsis or those undergoing cardiac surgery. In 2013, the European Medicines Agency (EMA) recommended the suspension of the marketing authorization of all HES solutions due to safety concerns, particularly in critically ill patients. Similarly, the US Food and Drug Administration (FDA) issued a safety communication in 2017 warning about the increased risk of mortality and kidney injury associated with HES solutions. Moreover, there is a growing preference for alternative fluid resuscitation strategies, such as crystalloid solutions and albumin, which are considered safer and more cost-effective than HES solutions. Crystalloid solutions are widely available, less expensive, and have fewer associated adverse effects. On the other hand, albumin has been shown to be safe and effective in certain patient populations, such as those with severe sepsis.
As healthcare infrastructure continues to develop and access to healthcare improves in countries such as India and China, the demand for HES solutions is expected to increase significantly. Moreover, there is a growing trend towards developing novel HES solutions with improved safety and efficacy profiles. Major market plyaers are investing in research and development to produce HES solutions with lower molecular weight and improved pharmacokinetics, which could reduce adverse events and increase efficacy. In addition, the expanding use of HES solutions in veterinary medicine presents an opportunity for growth in the HES solutions market. HES solutions are commonly used in veterinary medicine for fluid resuscitation, and the market for animal healthcare is expected to grow significantly in the forecast period. Thus, the increasing demand for HES solutions in emerging markets, the development of novel HES solutions, and the expanding use of HES solutions in veterinary medicine present opportunistic factors for the HES solutions market. As the demand for safe and effective fluid resuscitation strategies continues to rise, the HES solutions market will likely continue to evolve and grow.
The study categorizes the hydroxyethyl starch solutions market based on product type, end-user, and application area at the regional and global levels.
Based on the application, the market is divided into volume expansion, blood volume substitution, and others. The volume expansion segment is expected to dominate the market share in 2022 in the global hydroxyethyl starch solutions market. This is primarily due to the widespread use of HES solutions in surgical procedures and critical care settings, where volume expansion is a common therapeutic approach. However, the blood volume substitution segment is also expected to witness significant growth, driven by factors such as the increasing prevalence of hemorrhagic shock and trauma and the development of novel HES solutions with improved efficacy and safety profiles.
Based on the regions, the global hydroxyethyl starch solutions market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America is projected to account for the highest market share in 2022 due to factors such as the high prevalence of chronic diseases, increasing surgical procedures, and well-established healthcare infrastructure. Moreover, the presence of several major players in the HES solutions market, such as Fresenius Kabi AG and B. Braun Melsungen AG, further supports the market growth in North America. These companies have significant market shares and continue to invest in research and development to improve the safety and efficacy of HES solutions. Additionally, the increasing focus on patient safety and the growing preference for alternative fluid resuscitation strategies, such as crystalloid solutions and albumin, may present challenges for the HES solutions market in North America.
The hydroxyethyl starch solutions market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Metagenomics Sequencing Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024